There is strong clinical evidence to support the use of diagnostic Placental Growth Factor (PlGF) testing in the second and third trimesters for early preeclampsia detection, and growing evidence to support its use in the prediction / management of fetal growth restriction.However, as centres across the country move to adopt a national PlGF-testing implementation strategy, there are important bioethical issues to consider.These include individual considerations, relating to the bioethical principles of autonomy, beneficence, non-maleficence, and justice, as well as moral considerations involved in health technology assessment and epistemic bioethical concerns at the systems level.These relate to resource allocation, trade-offs and cost-effectiveness, as well as risk management and practical considerations around informed consent, professional liability, and the physician-patient relationship. RsumIl existe des donnes cliniques probantes en faveur du recours au dosage diagnostique du facteur de croissance placentaire (PlGF) aux deuxime et troisime trimestres pour la dtection prcoce de la pr-clampsie, ainsi qu'un nombre croissant de donnes probantes en faveur de son utilisation pour la prdiction et la prise en charge du retard de croissance intra-utrin.Cependant, alors que les tablissements du pays s'apprtent adopter une stratgie nationale de mise en oeuvre du dosage diagnostique du PlGF, d'importants aspects biothiques doivent tre tudis.Il s'agit notamment de facteurs individuels lis aux principes biothiques d'autonomie, de bienfaisance, de non-malfaisance et de justice, ainsi que de facteurs moraux lis l'valuation des technologies de la sant et aux aspects biothiques pistmiques l'chelle des systmes.
Zur et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: